Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Two better than one where lowering blood pressure is concerned

15.03.2004


A new set of guidelines for lowering blood pressure has been published by the British Hypertension Society (BHS) today. Their main recommendation is that most people with hypertension should be on two blood pressure lowering drugs rather than one.



The guidelines which are aimed at UK doctors, are published in summary form in the BMJ today (12 March), and represent best practice in treating UK patients for hypertension.

People with a blood pressure higher than 140/90 (mm Hg) are classified as having high blood pressure or hypertension.


Some 42 per cent of people in the UK aged between 35 and 64 are estimated to have hypertension, which puts them at a greatly increased risk of heart attacks and strokes.

Basing their guidelines on new data from clinical trials and safety tests of anti-hypertensive drugs, the guidelines say that for the best results in the UK, doctors must aim to get the blood pressure of their patients as low as possible, and for many that means taking a combination of the presently available drugs.

BHS President, Professor Neil Poulter of Imperial College London and St Mary’s hospital, Paddington, and co-author of the BMJ paper said:

"We suggest that two-thirds of people with hypertension should be on two drugs not one to get them down to their target blood pressure.

"But we know that 60 per cent of people on treatment for hypertension are receiving just one blood pressure lowering drug, meaning that many people are missing out on what we consider the best standard of treatment in this country.

The guidelines, authored by the Guidelines Committee of the British Hypertension Society, also suggest a simple ’AB/CD protocol’ to help doctors combine the different classes of blood pressure lowering drugs to provide the best treatment.

For those under 55, they say start with an ACE Inhibitor (or an Angiotensin receptor blocker) or a Beta blocker, and then if the target lower blood pressure is not reached, to use either a Calcium channel inhibitor or a Diruretic in addition, until the target is reached.

For those over 55, they suggest starting with a Calcium channel inhibitor or a Diruretic first, and if the target lower blood pressure is not reached, to use an ACE Inhibitor (or an Angiotensin receptor blocker) or a Beta blocker in addition.

For black patients they recommend using the same protocol as suggested for those over 55, regardless of patient’s age, as the ’C and D’ drugs are more effective on older people and in the black population than ’A and B’ drugs. This is because older people and black people have less natural renin than non-black (white and asian) and younger people, and C and D drugs work better than A and B where renin levels are low.

The BHS guidelines were last revised in 1999. Specialists in the field representing over 12 different stakeholder organisations including the British Hearth Foundation, the Royal College of General Practitioners and the UK Department of Health contributed to the latest guidelines.


For further information, please contact:

Professor Neil Poulter
International Centre for Circulatory Health
Imperial College London and St Mary’s Hospital, London
Tel: 44-207-594-3446
Email: n.poulter@imperial.ac.uk

Tony Stephenson
Imperial College London Press Office
Tel: 44-207-594-6712
Mobile: 44-775-373-9766
E-mail: at.stephenson@imperial.ac.uk

Tony Stephenson | alfa
Further information:
http://www.imperial.ac.uk
http://www.bmj.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>